Spinocerebellar ataxia (SCA) is a group of rare inherited disorders that cause progressive problems related to movement of the body. It is thought to affect between 10 and 25 of every 100,000 people in the general population. Symptoms generally begin in childhood and worsen as individuals age, although some forms of the condition can present in adulthood. The severity of symptoms varies from person to person, depending on the type and course of the disorder. SCA is caused by genetic mutations in a variety of genes responsible for controlling the balance, coordination, and muscle control of the body. The form and progression of the disease can vary from one individual to another, although common symptoms may include difficulty with coordination, particularly of limb movement, unsteady gait, and impaired speech. Other symptoms may include tremors, problems swallowing or speaking, clumsiness when using the hands, and a feeling of stiffness or tightness in the muscles. Diagnosis of SCA is usually based on a combination of clinical examination, laboratory and imaging tests, family history, and genetic testing. A thorough medical workup can help rule out other conditions that may have similar symptoms. Treatment for SCA usually involves medication to help control symptoms, as well as physical, occupational, and speech therapy. In some cases, patients may benefit from orthopedic supports or braces. The outlook for individuals with SCA depends on the type of condition and its severity, although there is unfortunately no known cure. Despite this, treatments may help improve symptoms and manage progression of the disease. Those affected by SCA should speak with their doctor to learn more about their specific form and what treatments may be best for them.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States